Ultrase MT12 and ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: Safety and efficacy

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 11-12, 2004, Pages 1365-1371

  Konstan, M W ^a   Stern, R C ^a   Trout, J R ^b   Sherman, J M ^c   Eigen, H ^d   Wagener, J S ^e   Duggan, C ^f   Wohl, M E B ^f   Colin, P ^g  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d RILEY HOSPITAL FOR CHILDREN   (United States)

^e CHILDREN S HOSPITAL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g Axcan Pharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PANCRELIPASE; PLACEBO; TRIACYLGLYCEROL LIPASE; ULTRASE MT12; ULTRASE MT20;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ENTERIC COATED TABLET; FEMALE; FLATULENCE; HEADACHE; HUMAN; INTESTINE OBSTRUCTION; LIPID ABSORPTION; MALABSORPTION; MALE; MALNUTRITION; NAUSEA; PANCREAS INSUFFICIENCY; PHARYNGITIS; PRIORITY JOURNAL; PROTEIN INTAKE; RECTUM DISEASE; RHINITIS; SCHOOL CHILD; SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AGED; CHILD; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LIPASE; MALE; MIDDLE AGED;

EID: 11144346971     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02261.x     Document Type: Article

References (12)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis: state of the art. Am J Respir Crit Care Med 1996; 154: 1229-56.
2. Stern RC, Eisenberg JD, Wagener JS, et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 2000; 95: 1932-8.
3. Gow R, Francis P, Bradbear R, et al. Comparative study of varying regimes to improve steatorrhea and creatorrhea in cystic fibrosis: effectiveness of an enteric-coated preparation with and without antacids and cimetidine. Lancet 1981; 2: 1071-4.
4. Blackfan KD, May CD. Inspissation of secretion, dilatation of the ducts and acini, atrophy and fibrosis of the pancreas in infants. J Pediatr 1938; 13: 627-34.
5. Kraisinger M, Hochhaus G, Stecenko A, et al. Clinical pharmacology of pancreatic enzymes in subjects with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994; 34: 158-66.
6. Brady MS, Richard K, Yu PL, et al. Effectiveness of enteric coated pancreatic enzymes given before meals in reducing steatorrhea in children with cystic fibrosis. J Am Diet Assoc 1992; 92: 813-7.
7. Borowitz DS, Grand RJ, Durie PR, et al. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr 1995; 127: 681-4.
8. Ultrase®MT12 and Ultrase®MT20 product description. Physicians Desk Reference, 58th edn. Montvale, NJ: Thomson PDR, 2004.
9. Stapleton FB, Kennedy J, Linshaw MA, et al. Hyperuricemia due to high-dose pancreatic extract therapy in cystic fibrosis. N Engl J Med 1976; 295: 246-8.
10. Mitchell EA, Quested C, Marks RE, et al. Comparative trial of viokase, pancreatin and pancrease pancrelipase (enteric coated beads) in the treatment of malabsorption in cystic fibrosis. Aust Paediatr J 1982; 18: 114-7.
11. Ansaldi-Balocco N, Santini B, Sarchi C. Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same subjects at two different ages. J Pediatr Gastroenterol Nutr 1988; 7 (Suppl. 1): S40-5.
12. Roberts IM. Enzyme therapy for malabsorption in exocrine pancreatic insufficiency. Pancreas 1989; 4: 496-503.